Gilead Sciences | GILD - Ebit

Stock Price
147.63
Daily Change
-2.20 -1.47%
Monthly
7.15%
Yearly
32.37%
Q1 Forecast
146.71

Gilead Sciences reported $2.96B in EBIT for its fiscal quarter ending in December of 2025.





Ebit Change Date
AbbVie USD 5.81B 4.36B Dec/2025
Agios Pharmaceuticals USD -121.58M 4.71M Dec/2025
ALKERMES USD 89.08M 3.9M Sep/2025
Alnylam Pharmaceuticals USD 29.4M 59.36M Dec/2025
Amgen USD 3.96B 464M Dec/2025
Biogen USD 659.6M 157M Sep/2025
BioMarin Pharmaceutical USD 198.39M 230.08M Dec/2025
Bristol-Myers Squibb USD 3.47B 567M Dec/2025
Coherus Biosciences USD -45.43M 3.19M Mar/2025
Eli Lilly USD 8.99B 1.57B Dec/2025
Gilead Sciences USD 2.96B 551M Dec/2025
GlaxoSmithKline GBP 1.44B 1.35B Dec/2025
Glaxosmithkline GBP 3.76B 1.69B Sep/2025
Incyte USD 383.88M 47.44M Dec/2025
J&J USD 5.11B 2.3B Dec/2025
Merck USD 6.24B 1.32B Dec/2025
Moderna USD -857M 597M Dec/2025
Neurocrine Biosciences USD 227.9M 11.4M Dec/2025
Novartis USD -9.19B 13.87B Jun/2025
Pfizer USD 4.65B 71M Dec/2025
PTC Therapeutics USD -81.62M 85.11M Dec/2025
Puma Biotechnology USD -2.2M 11.41M Jun/2024
Regeneron Pharmaceuticals USD 898.6M 211.3M Dec/2025
Sanofi EUR 1.7B 2.17B Dec/2025
Sarepta Therapeutics USD -62.88M 178.46M Sep/2025
United Therapeutics USD 389.3M 112.4M Sep/2025
Vertex Pharmaceuticals USD 1.26B 24.5M Dec/2025